Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320 · View on ClinicalTrials.gov ↗
Study Summary
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG ABBV-932
- DRUG Placebo for ABBV-932
- DRUG Antidepressant Therapy (ADT)
Study Locations (20)
California
- Advanced Research Center /ID# 267874 — Anaheim
- Axiom Research /ID# 267814 — Colton
- Sun Valley Research Center /ID# 267864 — Imperial
- Synergy San Diego /ID# 267879 — Lemon Grove
- Alliance for Research Alliance for Wellness /ID# 267911 — Long Beach
- NRC Research Institute DTLA /ID# 267832 — Los Angeles
- Excell Research /ID# 267918 — Oceanside
- Viking Clinical Research Center - Temecula /ID# 268598 — Temecula
- Sunwise Clinical Research /ID# 267863 — Walnut Creek
Florida
- Cns Healthcare - Jacksonville /ID# 268588 — Jacksonville
- Accel Research Sites Network - St. Pete /ID# 267821 — Largo
- K2 Medical Research, LLC /ID# 267841 — Maitland
- GMI Florida - Central Miami Medical Institute /ID# 267839 — Miami
- Allied Biomedical Res Inst Inc /ID# 267813 — Miami
- Apg Research /ID# 271707 — Orlando
Arizona
- Ima Clinical Research Phoenix (Alea) /ID# 275737 — Phoenix
- Noble Clinical Research /ID# 267952 — Tucson
Alabama
- University of Alabama - Huntsville Regional Medical Campus /ID# 267818 — Huntsville
Connecticut
- Connecticut Clinical Research - Cromwell /ID# 271241 — Cromwell
Georgia
- Psych Atlanta /ID# 267878 — Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846320
The ClinicalTrials.gov registry entry for NCT06846320 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Generalized Anxiety Disorder (GAD) appearing as the primary indexed condition, and to 3 interventions — of which ABBV-932 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06846320 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06846320 about?
NCT06846320 is a clinical study titled "Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder". Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants wi...
What is the current status of trial NCT06846320?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2025-04-29. Estimated completion is 2026-11.
What conditions does trial NCT06846320 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder (GAD). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06846320?
The interventions under investigation include: ABBV-932 (DRUG), Placebo for ABBV-932 (DRUG), Antidepressant Therapy (ADT) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06846320?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06846320 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.